Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andrzej Jakubowiak
University of Chicago Comprehensive Cancer Center
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University Health Network - Princess Margaret Cancer Center
Toronto, Ontario, Canada
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
- Wayne State University - Karmonos Cancer Center
Detroit, Michigan, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Aug 2012
- Primary completion
- 14 Nov 2025
- Completion
- 14 Nov 2025
- Last update posted
- 22 Dec 2025
- Registered enrollment
- 25
- Registry id
- NCT01665794
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.